Kazia Therapeutics
KZIA
9 hedge funds and large institutions have $116K invested in Kazia Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 10 closing their positions.
0.03% less ownership
Funds ownership: 0.04% → 0% (-0.03%)
47% less funds holding
Funds holding: 17 → 9 (-8)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
95% less capital invested
Capital invested by funds: $2.24M → $116K (-$2.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$10.8K |
| 2 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$3.34K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$734 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$150 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.09M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$801K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$65.9K |
| 4 |
Morgan Stanley
New York
|
-$61.5K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$12K |
KZIA Hedge Fund Activity: Q1 2024 in Review
9 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q1 2024, worth a combined $116K — down 95% from $2.24M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of KZIA and 2 opened new positions — a net loss of 8 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $10.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.09M sold.
- 9 institutional investors held Kazia Therapeutics (KZIA) as of Q1 2024, down from 17 in Q4 2023.
- Funds reported $116K of Kazia Therapeutics stock for Q1 2024, down 95% quarter-over-quarter.
- 2 funds opened new Kazia Therapeutics positions in Q1 2024 and 10 closed out, a net change of -8 holders.
- The largest Kazia Therapeutics buyer in Q1 2024 was BNP Paribas Financial Markets, an estimated $10.8K added.
- The largest Kazia Therapeutics seller in Q1 2024 was Armistice Capital, an estimated $1.09M sold.
Based on aggregated 13F filings for Q1 2024.